Skip to main navigation

About

Our Story Executive Team Board of Directors

Technology and Platforms

Our Approach FasTCAR TruUCAR Manufacturing

Pipeline

Investors

Overview News & Events Financial Information Stock Information Corporate Governance IR Resources Contact Us

Publications

Overview
News & Events
Financial Information
Stock Information
Corporate Governance
IR Resources
Contact Us

News & Events menu

News Releases
Events & Presentations
Publications

Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)

Published:

June, 2022

Source

2022 EHA Annual Congress Abstract

Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeti…

First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Published:

June, 2022

Source

2022 EHA Annual Congress Abstract

First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients …

Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Published:

June, 2022

Source

2022 EHA Annual Congress Abstract

Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Pa…

Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)

Published:

June, 2022

Source

Journal of Clinical Oncology / 2022 ASCO Annual Meeting Abstract

Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeti…

Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Published:

June, 2022

Source

Cancer Research / 2022 AACR Annual Meeting Abstract

Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in pa…

IL-2 Variant Improves CAR-T Functionality and Efficacy Against Solid Tumors

Published:

November, 2021

Source

Journal for Immuno Therapy of Cancer / 2021 SITC Annual Meeting Abstract

IL-2 Variant Improves CAR-T Functionality and Efficacy Against Solid Tumors

Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies

Published:

November, 2021

Source

Blood / 2021 ASH Annual Meeting Abstract

Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell T…

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

Published:

August, 2021

Source

Cellular & Molecular Immunology

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positiv…

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma

Published:

May, 2021

Source

Journal of Clinical Oncology / 2021 ASCO Annual Meeting Abstract

Long-term follow-up results of a multicenter first-in-human study of the dual B…

Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)

Published:

April, 2021

Source

2021 AACR Annual Meeting Abstract

Updates on clinical safety and efficacy result of GC027, the first-in-human, “O…

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management

Published:

March, 2021

Source

Clinical Cancer Research

Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Te…

Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform Fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma

Published:

December, 2020

Source

62nd ASH Annual Meeting, Oral Abstract

Clinical results of a multicenter study of the first-in-human dual BCMA and CD1…

Successful 24-hours manufacture of anti-CD19/CD22 dual chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL)

Published:

December, 2020

Source

62nd ASH Annual Meeting, Oral Abstract

Successful 24-hours manufacture of anti-CD19/CD22 dual chimeric antigen recepto…

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

Published:

October, 2020

Source

Leukemia

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post al…

Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)

Published:

April, 2020

Source

2020 AACR Annual Meeting Abstract

Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, unive…

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports

Published:

July, 2019

Source

Medicine

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports 310.5 KB

Shareholder Tools

Contact Us
Email Alerts
FAQs
RSS Feeds

Footer Links

Terms & Conditions
Privacy Policy
Contact Us
Careers